Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Financial disclosures
- Outline
- What is it?
- Pancreatogenic diabetes
- What's in a name?
- Type 3c diabetes mellitus
- How common is it?
- Confusion and overlap with T2DM
- Why does it matter?
- Distinguishing pancreatogenic diabetes from T2DM is clinically significant
- Worse glycemic control and earlier need for insulin
- Long-term microvascular complication and earlier onset of hypoglycemia
- Early diagnosis of pancreatic cancer
- Early detection of pancreatic cancer: a potential approach
- Nonvascular complications in pancreatogenic DM
- Disease-related complications of pancreatitis
- How do we diagnose it?
- How do we diagnose pancreatic diabetes?
- How do we classify pancreatogenic DM (1)
- How do we classify pancreatogenic DM (2)
- Key knowledge gap
- How should we treat it?
- Guidance of treatment decisions (1)
- Guidance of treatment decisions (2)
- What have we recently learned?
- Epidemiology of diabetes in pancreatitis
- Pathophysiology of pancreatogenic diabetes
- The potential role of autoimmunity
- The DREAM study
- Chronic pancreatitis and pancreatic cancer
- What are the next steps forward?
- Key opportunities (1)
- Key opportunities (2)
- Summary
- Acknowledgements
Topics Covered
- Pancreatogenic diabetes
- Type 3c diabetes
- Acute pancreatitis
- Chronic pancreatitis
- Pancreatic cancer
- Diagnosis of pancreatogenic diabetes
- Epidemiology of diabetes in pancreatitis
- Pancreatitis
Links
Categories:
Therapeutic Areas:
Talk Citation
Hart, P. (2023, March 30). Pancreatogenic diabetes: what is it and what to do about it? [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/KAYD6580.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Hart is a consultant for Kangen Pharmaceuticals and Sagent Pharmaceuticals.
A selection of talks on Metabolism & Nutrition
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, I'm Phil Hart,
Professor of Medicine at
the Ohio State University.
Today we'll be discussing
pancreatogenic diabetes,
including what is it,
what to do about it?
0:12
Here are my potentially
relevant financial disclosures.
0:17
In this session we'll be
covering pancreatogenic
diabetes from a number of
facets including
discussing what is it?
Why does it matter?
How do we diagnose it?
How should we treat it?
Then we'll move on to
discuss what have we learned
recently regarding
this condition,
and what are the
next steps forward?
0:35
To begin, we'll try
to define what is it.
0:40
Pancreatogenic diabetes
refers to diabetes that
occurs secondary to any disease
of the exocrine pancreas.
This can include acute
or chronic pancreatitis,
cystic fibrosis, hemochromatosis,
pancreatic cancer,
or following pancreatic surgery,
either a partial pancreatectomy
or total pancreatectomy.
It's important to understand
that pancreatogenic diabetes is
an umbrella term that really
describes a collection
of different entities.
As a consequence of this,
it represents a heterogeneous
mix of conditions,
each of which, we believe, have
unique aspects of
pathophysiology,
and as a result of this,
potential considerations
as it relates to treatment.
1:25
There are a number
of synonyms that are
currently used to describe
pancreatogenic diabetes.
The most common alternative
term is type 3c diabetes,
which we'll touch on
more in a moment here.
You can see there's a list of
four or five other synonyms
for this group of disorders.
As Shakespeare described
in Romeo and Juliet,
what something is called or
labeled is often
arbitrary and less
important compared to its
underlying intrinsic qualities,
which we'll describe
in more detail.